

administering to a patient a humanized anti-PHTrP antibody capable of inhibiting the binding between PTHrP and a receptor thereof and

allowing the antibody to inhibit the binding of PTHrP to a receptor thereof; wherein the patient has a blood calcium level above 10.4 mg/dl prior to treatment.

4. (Twice Amended) The method according to claim 1, wherein the humanized anti-PTHrP antibody is an antibody fragment capable of inhibiting the binding between PTHrP and a receptor thereof.

6. (Twice Amended) The method according to claim 1, wherein the humanized antibody is humanized #23-57-137-1 antibody.

7. (Twice Amended) The method according to claim 1 or 4, wherein the antibody is a monoclonal antibody.

Please add new claims 9-12 as follows:

--9. (New) The method according to claim 1, wherein the hypercalcemic crisis is associated with a coma and/or cardiac arrest.

10. (New) The method according to claim 1 or 4, wherein the antibody is bound to a carrier.

11. (New) The method according to claim 10, wherein the carrier is PEG.

12. (New) The method according to claim 4, wherein the antibody fragment is Fab, scFv, F(ab')₂, or Fv.--

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com